Portage Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PRTG Nasdaq 8731 https://portagebiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Portage Biotech Inc

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives - Apr 12th, 2024 12:01 pm
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares - Mar 26th, 2024 12:01 pm
PRTG: Extending the Runway - Mar 11th, 2024 10:24 am
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update - Feb 28th, 2024 10:10 pm
PRTG: Bridging I-O: Working in Harmony with Checkpoints - Jan 8th, 2024 9:18 am
Portage Biotech Reports Business and Strategic Update - Jan 4th, 2024 1:00 pm
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update - Nov 28th, 2023 9:01 pm
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting - Nov 6th, 2023 1:01 pm
Portage Biotech Announces $6.0 Million Registered Direct Offering - Sep 29th, 2023 12:00 pm
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference - Sep 20th, 2023 12:00 pm
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors - Sep 5th, 2023 12:00 pm
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update - Jul 31st, 2023 8:05 pm
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors - Jun 26th, 2023 12:00 pm
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting - Jun 5th, 2023 12:00 pm
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference - Jun 1st, 2023 12:00 pm
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 26th, 2023 9:00 pm